Search
Displaying 461–470 of 1063 results
-
Beacon Stories
At only three months old, Brendon was diagnosed with x-linked juvenile retinoschisis (XLRS). But with several other family members also with XLRS, Brendon knew he could still follow his passions for science and space. Now 22, Brendon is an Aerospace Engineer, starting a PhD program at UCF, and was recently awarded the prestigious National Science Foundation’s Graduate Research Fellowship.
-
Foundation News
This December 16th exclusive in-person performance and conversation with the Blind Boys of Alabama will raise awareness for blinding diseases.
-
In the Press
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
-
Fundraiser Success Stories
Sean Teare has completed a marathon and a triathlon as DIY fundraisers for the Foundation Fighting Blindness.
-
Beacon Stories
At the age of five, Livie was diagnosed with LCA but her doctor immediately told her parents that clinical trials were underway and that Livie could soon be eligible for treatment. Not long after, they got a phone call from Spark Therapeutics and Livie received LUXTURNA®. Now eight, Livie’s confidence is at an all-time high with her “new eyes.”
-
June 17–June 18, 2022. Disney’s Coronado Springs Resort, Orlando, FL. VISIONS 2022, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, hear about exciting advancements in blindness research.
-
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Foundation NewsPatient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Seeing Research Advances Firsthand
Beacon StoriesMark does not let his retinitis pigmentosa diagnosis keep him from doing what he loves most, including spending quality time with his family. And in 2019, Mark began participating in a clinical trial, which he describes as life-changing.
-
Opus Genetics Announces Two Key Leadership Appointments
In the PressDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
.png)
